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Background: G-protein-coupled receptors (GPCRs) are important drug targets and a better understanding of
their molecular mechanisms would be desirable. The crystallization rate of GPCRs has accelerated in recent years
as techniques have become more sophisticated, particularly with respect to Class A GPCRs interacting with G-proteins.
These developments have made it possible for a quantitative analysis of GPCR geometrical features and binding-site
conformations, including a statistical comparison between Class A GPCRs in active (agonist-bound) and inactive
(antagonist-bound) states.
Results: Here we implement algorithms for the analysis of interhelical angles, distances, interactions and binding-site
volumes in the transmembrane domains of 25 Class A GPCRs (7 active and 18 inactive). Two interhelical angles change
in a statistically significant way between average inactive and active states: TM3-TM6 (by -9°) and TM6-TM7 (by +12°).
A third interhelical angle: TM5-TM6 shows a trend, changing by -9°. In the transition from inactive to active states,
average van der Waals interactions between TM3 and TM7 significantly increase as the average distance between
them decreases by >2 Å. Average H-bonding between TM3 and TM6 decreases but is seemingly compensated by
an increase in H-bonding between TM5 and TM6. In five Class A GPCRs, crystallized in both active and inactive states,
increased H-bonding of agonists to TM6 and TM7, relative to antagonists, is observed. These protein-agonist
interactions likely favour a change in the TM6-TM7 angle, which creates a narrowing in the binding pocket of
activated receptors and an average ~200 Å3 reduction in volume.
Conclusions: In terms of similar conformational changes and agonist binding pattern, Class A GPCRs appear to
share a common mechanism of activation, which can be exploited in future drug development.
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G-protein-coupled receptors (GPCRs) are the largest
superfamily of signalling molecules in the human gen-
ome with approximately 800 genes, each containing a
seven-helix transmembrane domain (7TM) [1]. GPCRs
are distributed throughout the body in cellular mem-
branes and act as conduits, binding extracellular ligands
(neurotransmitters, hormones, lipids, peptides, drugs) or
capturing light photons (in the case of rhodopsin),
converting the energy they embody into intracellular re-
sponses by stabilizing certain receptor conformational
states, in turn influencing intracellular binding of guanine
nucleotide-binding proteins (G-proteins) or β-arrestin* Correspondence: jesus.giraldo@uab.es
Laboratory of Molecular Neuropharmacology and Bioinformatics, Institut de
Neurociències and Unitat de Bioestadística, Universitat Autònoma de
Barcelona, 08193 Bellaterra, Spain
© 2015 Dalton et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[2,3]. As GPCRs are highly abundant in the human body
and involved in many diverse signalling pathways (e.g.
metabolic, regulatory, immunological, neurological), as
well as typically binding small ligands, they serve as excel-
lent drug targets [4]. GPCRs are currently targeted by
~40% of today’s marketed drugs and it is likely that their
potential “druggability” is even greater [5]. Indeed, of the
370 non-olfactory GPCRs, 59 have already been drugged
with small molecules [6].
Despite their known importance as drugs targets and
role in human disease [5], the mechanisms that precisely
control GPCR ligand binding and receptor activation
have until very recently been hindered by a lack of
structural knowledge, in particular due to a relative lack
of crystallized active receptor states and receptor-ligand
complexes. GPCRs are grouped into distinct classes
with Class A (or rhodopsin-like) being the largest andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tures, mostly in their inactive state. However, significant
advances in crystallization has recently permitted the
structural determination of several Class A receptors in
active (agonist-bound and sometimes G-protein bound)
states, i.e. β2-adrenergic [7], adenosine A2A [8], metar-
hodopsin II [9], neurotension NTS1 [10], acetyl choline
muscarinic M2 [11], and P2Y12 [12] receptors. These
active structures have significantly added diversity and
detail to GPCR structural knowledge, which before
them was primarily limited to the inactive structures of
rhodopsin (first crystallized in 2000 [13]), antagonist-
bound β2/1-adrenergic (crystallized in 2007 [14] and
2008 [15]) and adenosine A2A receptors (crystallized in
2008 [16]). Furthermore, in addition to the recent emer-
gence of several active structures, several more Class A
receptors have been crystallized in their inactive
antagonist-bound state, e.g. mu- [17], kappa- [18],
delta- [19], N/OFQ- [20] opioid receptors, muscarinic
M2 receptor [21], chemokine receptors CXCR4 [22] and
CCR5 [23], and protease-activated receptor 1 (PAR1) [24].
As a consequence, several studies have taken advantage
of these recent developments in crystallization and
attempted to identify various activation mechanisms in
Class A GPCRs, primarily through visual comparison of
specific receptor structures in inactive and active states
[25-29]. Some studies have also identified specific
“micro-switches”, i.e. small groups of residues that
undergo conformational change during receptor acti-
vation [30-32]. Molecular dynamics has been used to
investigate pathways of activation in Class A receptors,
such as β2-adrenergic [33-35]), adenosine A2A [36],
muscarinic acetylcholine M2 [37,38], S1P1 [39] and
rhodopsin [40]. Several intrahelical features have also
been identified as important in GPCR structure and
function, such as kinks or α-bulges, often near prolines
in highly conserved positions [41-43], and sulphur-
containing residues acting as molecular gears [44].
Biased signalling, i.e. different ligands selecting for
different intracellular binding partners, is another area
that is gaining particular attention [45-48], such as β2-
adrenergic receptor adopting different conformations of
TM6 for selective Gi or Gs binding [49], enhancement
of β-arrestin over G-protein binding with δ-opioid re-
ceptor through disruption of interhelical interfaces [19]
and serotonin 2A receptor where hallucinogenic and
non-hallucinogenic agonists respectively stabilize differ-
ent conformations of an intracellular loop region impli-
cated in partner binding [50].
However, although informative in their own way, none
of these studies have quantitatively assessed GPCR
conformational change at an overall level between active
and inactive states, nor utilised the extra number of
receptor structures that have recently become availableto provide increased statistical power. Furthermore, in
our opinion, an explanation of how the common func-
tional mechanisms that appear to be at work in GPCR
activation (e.g. suggested by [26]) are mediated through
agonist (or reversed in antagonist) binding has not yet
been convincingly made. Such an understanding would
greatly aid the design of new or more selective/biased
agonists or antagonists to target therapeutically import-
ant GPCRs, as well as explaining the effect that naturally
occurring mutations have on constitutive receptor activ-
ity and disease, or indeed predicting where mutations
could be inserted to intentionally modulate receptor
activity. We believe the opportunity for such analyses
has become possible due to the recent surge of new
crystal structures in varying states of activation. Here,
we present a quantifying analysis of GPCR conform-
ational change with statistical comparison, using a set of
25 Class A structures: 7 active and 18 inactive and two
algorithms: Helix Packing Pair [51] and POVME [52].
Our intention is to quantify existing theories of Class A
GPCR activation, as well as potentially discovering new
ones, and in doing so help to form a better understand-
ing of the common features governing receptor activa-
tion. However, we do not attempt to replicate specific
analyses of previous studies that focus on highly detailed
aspects of particular receptors or nuanced differences.
Instead we focus on overall conformational changes
between TM helices, which can be identified as being in
common across the whole Class A receptor family, as far
as is currently possible with the structures available. We
also seek to identify the most important aspects of
conformational change according to statistical signifi-
cance so that these can potentially be correlated with
agonist or antagonist binding patterns. Regarding the
algorithms we chose to employ, Helix Packing Pair
mathematically measures the dihedral angle between
packed helix pairs (see Figure 1 and Methods) as well as
measuring the extent of atomic interaction and distances
between helices [51], thereby detecting rotational and
translational movements of each helix and their chan-
ging interactions. POVME measures binding pocket
volume and shape and permits a mathematical compari-
son between different GPCR conformational binding-site
volumes. As a result, by combining the various data, an
internal geometrical picture of each GPCR can be made,
which can then be compared to different conformations
of a particular receptor or across different receptors
(independently of structural superimposition, which can
be prone to variation) or used to calculate average
features across all known GPCR states. Here we specific-
ally compare the geometrical features of active Class A
GPCR structures with respect to inactive structures,
both in terms of individual receptors and across the
family as a whole, and as a result identify the most
Figure 1 The interhelical dihedral angle: degree of rotation between
planes of two interacting helices defined by axis vectors and
perpendicular vector of closest approach. Helix pair interaction is
assessed by number of interhelical van der Waals contacts and H-bonds.
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changes involved. Furthermore, with respect to five
specific Class A receptors whose inactive and active
states are both known, including the recently released
P2Y purinoceptor 12 [12] and [53], we compare
protein-agonist and protein-antagonist interactions and
possibly identify a common means of agonist-mediated
action that likely stabilizes the active state.
Results
In order to quantify conformational changes in 25 Class
A GPCR crystal structures, 18 in the inactive state and 7
in the active state, an analysis was made with Helix
Packing Pair [51] to determine the orientation of helix
pairs in each 7TM domain and how these differ between
receptor states. Three conformational features were
assessed: (i) helix tilt by measuring degree of rotation
between contacting helices, i.e. their interhelical angle
from 0-90° (see Figure 1) [51], (ii) helix translation bymeasuring interhelical distances between centrally posi-
tioned and highly conserved residues in the core of each
receptor (see Additional file 1: Figure S1I and Methods),
(iii) interhelical interaction by counting the number of
van der Waals’ (vdWs), hydrogen bonds and electrostatic
contacts between helices. In total, in each receptor
twelve helix pairs are commonly observed with TM3
participating in five pairs, TM2 and TM7 participating
in four each, TM4, TM5 and TM6 in three each, and
TM1 in two (see Figure 2). In this context, TM3 can be
considered the central “hub” helix in the 7TM fold,
making the most interhelical packing contacts. The
interhelical angles, interhelical distances and interhelical
contacts in twelve helix pairs were compared across all
receptor structures with the average values for active
and inactive receptor states shown in Figure 3 (angles),
Figure 4 (distances), Figures 5 and 6 (vdWs and H-
bonds, respectively). In addition, the differences between
these states and hence overall conformational changes
are shown proportionally in Figure 2. Overall the average
interhelical angles involving TM3 remain mostly static
across inactive and active states as its tilt and that of
its interacting partners remain relatively constant. An
exception to this rule is the TM3-TM6 angle, which
undergoes a significant adjustment as the intracellular
end of TM6 tilts outwards during receptor activation,
becoming more parallel with respect to TM3 (an average
angle of 40° ±1 s.e.m. for inactive states and an average
of 31° ±2 s.e.m. for active states; t-test with Bonferroni
correction for multiple comparisons: p = 0.002). How-
ever, TM3 undergoes a significant translational move-
ment upwards and towards TM2, reducing the distance
between residues L/I/V/T3.40 and D2.50 (an average
distance of 11.4 Å ±0.1 s.e.m. for inactive states and an
average of 10.3 Å ±0.2 s.e.m. for active states; t-test with
Bonferroni correction: p = 0.001). The upward axial
movement of TM3 has been proposed before as a com-
ponent of receptor activation [26] but the sideways
movement towards TM2 also appears to be an import-
ant feature, contributing to a more compact 7TM fold.
As well as the interhelical angles involving TM3, the
angles involving TM1, TM2 and TM4 remain mostly
constant between active and inactive states, suggesting a
degree of rigidity in this side of the receptor. However,
noticeably greater differences are observed between
active and inactive states with respect to TM5, TM6 and
TM7. As already mentioned, the outward tilting of TM6
at the intracellular side seen in G-protein-bound acti-
vated receptors [7,9,11] (Additional file 1: Figure S2I) also
creates key changes in interhelical angles: TM5-TM6 and
TM6-TM7. The angle between TM5 and TM6 decreases
as these helices become more parallel (an average of
24° ±1 s.e.m. in inactive receptors and an average of
15° ±3 s.e.m. in active receptors; t-test: p = 0.025,
Figure 2 Helix pairs in Class A GPCRs. (A) Extracellular view of 7TM fold of the muscarinic acetylcholine M2 receptor (PDB id: 3UON). (B) 2D
representation of average conformational changes during receptor activation (from 18 inactive and 7 active Class A GPCRs). Helices are solid black
circles. Helix pairs connected with black dotted lines. Line width is proportional to change in interhelical angle. Circular arrows give angle rotation
direction: anticlockwise for angle decrease (helices become more parallel), clockwise for angle increase (helices become less parallel). Solid black
arrows show translational movement of helices.
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correction) while the angle between TM6 and TM7 in-
creases as these helices become less parallel (an average
of 9° ±1 s.e.m. in inactive receptors and an average of
21° ±2 s.e.m. in active receptors; t-test and Bonferroni
correction: p = 0.0001). These angle differences also
reflect a movement in the helices partnering TM6, i.e.
TM5 undergoes a minor tilt outwards at its intracellu-
lar side and TM7 tilts inwards at its intracellular side in
the reverse direction to TM6. The tilting of TM7 also
causes a minor reduction in the TM1-TM7 angle as
these two helices become more parallel (an average of
25° in inactive receptors compared to an average of 21°
in active receptors; t-test p = 0.120). There is also a
significant inward translational movement of TM7
towards TM3 (an average distance of 11.9 Å ±0.1 s.e.m.
for inactive states and an average of 9.6 Å ±0.5 s.e.m.
for active states; t-test with Bonferroni correction: p =
0.001), as well as a statistically significant increase in
the number of vdWs between these two helices inFigure 3 Average interhelical angles extracted from 18 inactive and 7 activ
statistical significance between inactive and active states with Student’s t-teactive receptor states (Wilcoxon rank-sum test with
Bonferroni correction for multiple comparisons: p =
0.009). Conformational change in TM7 can perhaps be
considered the most defining features of GPCR activa-
tion as it is statistically significant across all three con-
formational categories and is seemingly independent of
G-protein binding (only three of the seven active recep-
tor states contain an intracellular binding partner, see
Methods for details).
In general terms, the number of vdWs between packed
helices is greater in active states relative to inactive
states (Figure 5), suggesting a more compact fold in ac-
tivated receptors. With regards to H-bonds the picture
is more balanced with both losses and gains occurring
across all helix pairs, although a loss of interaction be-
tween helices TM3 and TM6 is noticeable although not
statistically significant (see Figure 6). This observation
partly reflects the loss of the “ionic lock” that occurs in
some receptors during activation as TM6 tilts outwards
on the intracellular side away from TM3 [9,26].e class A GPCR structures. Standard error bars are shown. *denotes
st after Bonferroni correction for multiple testing.
Figure 4 Average interhelical distances extracted from 18 inactive
and 7 active class A GPCR structures. Distances are calculated between
Cα atoms of central and highly conserved residues in the 7TM core:
G/I1.46, D2.50, I/V3.40, W4.50, P5.50, F6.44, S/C7.46 (Ballesteros-Weinstein
numbering [60]). Standard error bars are shown. *denotes statistical
significance between inactive and active states with Student’s t-test
after Bonferroni correction for multiple testing.
Dalton et al. BMC Bioinformatics  (2015) 16:124 Page 5 of 15Interestingly, the distance between TM3 and TM6 at
their midpoints does not change between active and in-
active states, suggesting that tilting of TM6 around its
centre point is responsible for conformational change
between TM3 and TM6 in G-protein-bound receptor
structures (see Additional file 1: Figure S2I) rather than
a translational movement. An increase in the number of
H-bonds between TM5 and TM6 is also noticeable in
active structures and is close to statistical significance
(Wilcoxon rank-sum p-value = 0.097) as is a translationalFigure 5 Boxplots of van der Waals atomic contacts between packed helix
statistical significance between inactive and active states with Wilcoxon ranmovement of TM5 towards TM6 (an average distance
of 11.7 Å ±0.2 s.e.m. for inactive states and an average
of 10.6 Å ±0.4 s.e.m. for active states; t-test p = 0.011,
although not statistically significant after Bonferroni
correction). These features are indicative of a stronger
interaction between TM5 and TM6, which has previ-
ously been described in B2AR and M2R activation [25].
In general terms, it is striking how the distances be-
tween helix pairs at their centre points (see Additional
file 1: Figure S1I) do not change much apart from the
three examples mentioned: TM3-TM7, TM2-TM3 and
TM5-TM6. Instead it appears that helix tilting is the
primary means of imparting conformational change in
Class A GPCRs, with changes in interhelical angles
mainly involving TM5, TM6 and TM7.
In order to inspect conformational changes in more
detail, interhelical angles and their effect on receptor
conformation were assessed in the inactive and active
states of five receptors: β2-adrenergic receptor (B2AR),
adenosine A2A receptor (A2AR), muscarinic acetylcho-
line M2 receptor (M2R), Rhodopsin (RHO), and P2Y
purinoceptor 12 (P2Y12R) (see Figures 7 and 8 for sim-
plified representations of conformational change). These
five receptors are the only GPCRs that have been crys-
tallized in both active and inactive states, although
A2AR and P2Y12R are only “semi-active” as they con-
tain no bound G-protein or stabilizing nanobody. The
interhelical angle changes observed in these five recep-
tors reflect the averages as one might expect, although
to differing degrees. The greatest conformational changepairs in 7 active and 18 inactive Class A GPCR structures. *denotes
k-sum test after Bonferroni correction for multiple testing.
Figure 6 Boxplots of H-bonds and electrostatic contacts between packed helix pairs in 7 active and 18 inactive Class A GPCR structures.
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G-protein e.g. B2AR and M2R, and to a lesser extent
RHO, which has a bound intracellular fragment. Some
conformational change is also apparent in “semi-active”
A2AR and P2Y12R, although it is more subtle. Taking
each helix pair at a time, the greatest change between
TM5 and TM6 occurs in M2R, where a shift of -22° is
observed during activation (Figure 7D). The smallest
change in the TM5-TM6 angle is observed in A2AR,
where a shift of -4° is explained by a relative lack of
movement in TM6 as a result of no bound G-protein
(Figure 7C). Likewise, the greatest change in the TM3-
TM6 angle occurs in M2R, with a shift of -20°, while
the smallest change is seen in RHO with -4°. With
regards to the TM6-TM7 angle, four receptors show a
significant change upon agonist-induced activation,
while in P2Y12R the change is more moderate. The
greatest is observed in B2AR where TM6-TM7 shifts
by +21° (Figure 7A) and is the lowest in P2Y12R with a
shift of +4° (Figure 7E), a result of no bound G-protein
and little intracellular movement of TM6. However,
more unusually, inward bending of TM6 towards the
orthosteric binding pocket on the extracellular side con-
tributes to a change in the TM6-TM7 angle in P2Y12R.
This demonstrates that although a common rotational
change between TM6 and TM7 occurs in (semi-)acti-
vated receptors, this conformational movement can be
delivered in different ways, either through a relative
tilting of TM6 with respect to TM7 or vice versa, or
indeed a combination of both in the larger conform-
ational change seen in fully activated receptors, e.g. B2ARand M2R. Likewise, despite no bound G-protein, a
significant change in the TM6-TM7 angle is observed
in the “semi-active” state of A2AR with a shift of +13°
(Figure 7C) due to an inward tilting of TM7 on the
intracellular side. In particular, this suggests that an
intracellular movement of TM7 is a pre-requisite step
for full activation, which is followed by intracellular
movement of TM6 and G-protein binding. All five re-
ceptors show an increased level of interaction between
TM3 and TM7, in agreement with average observations,
with the greatest change seen in B2AR and M2R,
reflecting their fully active status (see Additional file 1:
Figure S3I). Likewise, the interhelical TM3-TM7 dis-
tance decreases in all receptors with the greatest change
seen in A2AR, where residue S7.46 undergoes a shift
towards I3.40 by 5.3 Å (Additional file 1: Figure S4I).
However, in other receptors a shift of 1.5-2.4 Å is more
common.
In view of the observed movements of TM7 in relation
to TM3 and TM6, the interaction of TM6 and TM7 with
co-crystallized agonists and antagonists was compared
in five receptors (see Figures 8 and 9). RHO is different
from the others as its ligand (retinal) is covalently bound
to TM7 and undergoes a conformational switch upon
photo-activation, contributing to a different orientation
of TM7 (Figures 8A and 9A-B). The four other receptors
bind diffusible agonists/antagonists and changes in the
orientation of TM7 are observed between inactive and
active states in all (Figure 8). In the active state of
A2AR, where TM7 makes an intracellular inward tilt
with respect to TM6 (Figure 8B), the agonist UK-432097
Figure 7 The difference between interhelical angles in inactive and active states of Class A GPCRs: (A) β2-adrenergic receptor, (B) rhodopsin,
(C) adenosine A2A receptor, (D) muscarinic acetylcholine M2 receptor, (E) P2Y purinoceptor 12.
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Figure 8 Comparison of 7TM conformation (from extracellular side,
helices represented as cylinders calculated with CHIMERA [68]) in
inactive (red) and active (yellow) states of Class A GPCRs: (A) rhodopsin,
(B) adenosine A2A receptor, (C) β2-adrenergic receptor, (D) muscarinic
acetylcholine M2 receptor, (E) P2Y purinoceptor 12.
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state, the antagonist ZM241385 makes none (Figure 9C-
D). In addition, the agonist also makes an extra H-bond
with TM6. In the active and inactive states of B2AR, the
agonist (BI167107) and antagonist (carazolol) both make
two H-bonds with TM7, however unlike the antagonist,
the agonist makes an H-bond with TM6 (Figure 9E-F).
This may contribute extra stability to the different orien-
tation between TM6 and TM7 (Figure 8C). Furthermore,
the agonist in B2AR is shorter in length than its res-
pective antagonist, requiring a translation of TM7 to
maintain the H-bonding pattern. In the active state of
P2Y12R, an inward movement of TM7 is concomitant
with the agonist (2-methylthio-adenosine-5′-triphosphate)
making an H-bond with TM7, while an extracellular in-
ward movement of TM6 accommodates three H-bonds
between agonist and TM6 (Figures 8E and 9J). These
interactions are absent in the inactive state of P2Y12R,
where the antagonist (AZD1283) makes only a single
H-bond with TM6 (Figure 9I). Finally, M2R is different
from the other receptors as the crystal structure of the
active state contains an allosteric modulator (LY2119620)
as well as an agonist (iperoxo) (Figure 9H). Both the
antagonist (3-quinuclidinyl-benzilate) and iperoxo make a
classical H-bond with TM6 (Figure 9G-H) while the lat-
ter also forms a close CH–O interaction with Y7.39 (on
TM7). Furthermore, LY2119620 makes two H-bonds
with TM6 and TM7, respectively (Figure 9H). These
additional allosteric interactions may stabilise the ob-
served change in the TM6-TM7 angle (Figure 8D).
Therefore, taken together, the observed pattern of H-
bonding interactions in these five receptors suggests
agonist interactions with TM6 and TM7 encourage a
shift in the TM6-TM7 interhelical angle, while H-bonds
with TM7 additionally encourage a reduction in the
TM3-TM7 distance, both seemingly common features
of receptor activation, likely constituting the principal
mechanism of agonist action.
In order to investigate the effect changes in the TM3-
TM6, TM5-TM6 and TM6-TM7 interhelical angles, as
well as TM3-TM7 distance, have on the orthosteric
binding-site, pocket volume in five receptors: B2AR,
A2AR, M2R, RHO, and P2Y12R was calculated with
POVME [52] in inactive and active states, respectively.
This reveals a common conformational event that occurs
during activation in terms of both pocket shape and
volume (Figures 10 and 11). Regarding shape, the
binding-site in each receptor narrows as a result of the
Figure 9 A comparison of antagonists (magenta) in inactive states (pink) and agonists (teal) in active states (cyan) of Class A GPCRs: (A, B)
rhodopsin, (C, D) adenosine A2A, (E, F) β2-adrenergic, (G, H) muscarinic acetylcholine M2, (I, J) P2Y purinoceptor 12. Only side-chains on TM6
and TM7 that make covalent or H-bonds with antagonists/agonists are displayed. H-bonds shown as black lines, calculated with CHIMERA [68].
Agonists typically make more H-bonds with TM6/7 than respective antagonists.
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pocket volume significantly decreases during activation
by an average of -212 Å3 ± 108 s.e.m. (t-test p = 0.029),
a consequence of angle changes involving TM5, TM6
and TM7 and translation of TM7 and TM3. The one
exception to this rule is rhodopsin whose pocket volume
remains constant despite undergoing conformational
narrowing (Figure 10A-B). Rhodopsin may be a special
case as unlike the other receptors it does not bind a dif-
fusible ligand and has an internalized extracellular loop2, which traverses inside its 7TM domain. As a result,
rhodopsin has the smallest pocket compared to other
receptors (38-75% the size). This unusual feature likely
restricts rhodopsin from making more extensive con-
formational changes upon receptor (in)activation and
without needing to (un)bind its ligand, perhaps removes
the need for it to do so. The significant conformational
shift of TM7 is seemingly mediated by increased interac-
tions with agonists, which results in an increase in the
TM6-TM7 angle, reduction in TM3-TM7 distance and a
Figure 10 A comparison of inactive states (in pink) and active states
(in cyan) of Class A GPCRs (extracellular view): (A) and (B): adenosine
A2A receptor, (C) and (D): rhodopsin, (E) and (F): β2-adrenergic receptor,
investigate pathways of activation(G) and (H): muscarinic acetylcholine
M2 receptor, (I) and (J): P2Y purinoceptor12. Binding-site volumes
(in magenta) were calculated with POVME [52].
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activation varies between receptors, observed at its
greatest in M2R whose pocket decreases by -60%,followed by P2Y12R whose pocket decreases by -54%,
-40% in A2AR and -26% in B2AR (Figure 11). Neverthe-
less despite these differences in magnitude, it appears
that the five receptors function in a similar fashion, both
in terms of their relative reorientation of TM7, the bind-
ing mode of the agonist, and overall effect on binding-
pocket shape and volume. These suggest a common
functional mechanism.
The intracellular G-protein binding-site of Class A
GPCRs generally gets less attention than the orthosteric
ligand binding-site, although recent studies are address-
ing this [49,50,54]. In recognition, we also focussed
POVME on the intracellular side of the five receptors in
order to inspect conformational changes in the G-protein
binding-site. As three receptors are co-crystallized with a
bound intracellular partner (B2AR, M2R and rhodopsin),
we expected to see strong intracellular changes and re-
assuringly we did (see Additional file 1: Figures S5I and
S6I). In these three receptors, the intracellular G-protein
binding-site increases in volume by an average of 565
Å3 ± 20 s.e.m. (t-test p = 0.001) from inactive to active
state. This number is interesting as it is approximately
twice that of the observed average decrease in the orthos-
teric binding pocket upon agonist binding. This supports
the notion that conformational changes are amplified or
“doubled” from extracellular to intracellular sides [55].
A2AR and P2Y12R, who have no co-crystallized intra-
cellular partner, and despite apparent conformational
changes on their extracellular sides, show no statistical
volume changes in their intracellular G-protein binding-
sites. However despite this, there is clear intracellular con-
formational change, particularly with respect to A2AR,
whose outward tilting of TM6 and inward pinching of
TM7 creates a flatter, wider space (see Additional file 1:
Figure S5I). Binding of a G-protein would therefore likely
stabilize an even greater displacement of TM6 and create
a larger volume difference. P2Y12R also shows some
intracellular conformational differences but these are a re-
sult of subtle changes in the C-terminal structure of TM7
rather than helix tilting, with a partial unravelling of TM7
by half a helix-turn also changing the orientation of H8.
This has an effect of increasing the space between TM7
and TM2 and changing the shape of the pocket but not its
overall volume (Additional file 1: Figure S5I). However, in
way of caution, both the inactive and active states of
P2Y12R are crystallised with BRIL-fusion constructs
(between TM5 and TM6), meaning intracellular confor-
mational changes may be restricted.
Discussion and conclusions
Although comparative studies of GPCRs in active and
inactive states have been performed before [25-29], these
have generally been based on visual comparisons of
structural superimpositions, which can lead to different
Figure 11 Binding pocket volumes (Å3) in the inactive and active states of Class A GPCRs: β2-adrenergic receptor (B2AR), rhodopsin (RHO),
adenosine A2A receptor (A2AR), muscarinic acetylcholine M2 receptor (M2R), P2Y purinoceptor 12 (P2Y12R).
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formational changes in receptors are large or compari-
son between different receptors is difficult because of
alternative structural alignments. Here, we implement
quantifying methods for GPCR conformational analysis:
Helix Packing Pair [51] and POVME [52] that operate
independently of structural superimposition as each re-
ceptor structure is analysed internally, making for easier
comparison between active and inactive states. It also
allows for a statistical evaluation of the average differ-
ences between receptor states.
Despite the calculations involving different receptors,
as Class A GPCRs share many sequence and structural
features as well as G-protein binding partners [56], we
believe such comparisons are meaningful and can poten-
tially reveal common conformational changes and shared
mechanisms of agonist/antagonist action. The results
generated with a set of 25 Class A GPCRs, and subset of
five receptors in detail, suggest a common overall set of
conformational changes that occur during GPCR activa-
tion, and that these are mediated by agonist interaction
with TM6 and particularly TM7. The statistically signifi-
cant conformational changes in active states, with re-
spect to inactive, can be summarized as follows: (i) an
inward translation of TM7 with respect to TM3 and
tilting of TM7 with respect to TM6, increasing the
TM6-TM7 angle and increasing the interaction between
TM3 and TM7; (ii) a lateral and upward translation of
TM3, decreasing the distance between TM2 and TM3;
(iii) stabilized by G-protein binding, an outward tilting
of TM6 that increases the TM6-TM7 angle and de-
creases the TM3-TM6 angle (this also has trending
effects of decreasing the TM5-TM6 angle, decreasing TM3-
TM6 interaction and increasing TM5-TM6 interaction). Inan analysis with POVME in both active and inactive
states, the sum of these conformational changes results
in the narrowing of the orthosteric binding-site between
TM3 and TM6/TM7, significantly decreasing pocket
volume. On the intracellular side, significant increases
in volume of the G-protein binding-site are observed in
activated receptors with bound G-protein or derivatives,
which are approximately twice the size in magnitude of
changes on the extracellular side. Even in receptors with
no bound G-protein, some intracellular conformational
change is apparent, which may assist G-protein binding.
These observed changes suggest common conform-
ational change is apparent in an overall sense of Class A
GPCRs, which is mirrored by a repeating trend of
increased H-bonding by agonists to TM6 and TM7 with
respect to antagonists. Indeed, it is tempting to specu-
late that design of agonists through rational means
should include functional H-bonding groups for strong
contact with residues at the C-terminus of TM6 and
the N-terminus of TM7. Likewise, antagonists should
possibly be designed to preclude H-bonding with the N-
terminus of TM7 and to a lesser extent with TM6 as
well, although potentially still H-bonding with the N-
terminus of TM3, which may act as an “anchor”.
Another interesting aspect of GPCRs is the contribu-
tion this family of receptors makes to human disease
through naturally occurring mutations that result in loss
or gain of constitutive activity. Strikingly, of those muta-
tions that are documented in various Class A GPCRs, a
large proportion are located on TM6 and TM7, particu-
larly at their mutual interface, which appears to confirm
the functional importance of TM6 and TM7 conform-
ational change. Other mutations are also found on TM3
or TM5 in their respective interfaces with TM6 or TM7
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for example, mutation of K7.43 or E3.49 (Ballesteros-
Weinstein numbering [60]) in rhodopsin affects retinal
binding and eradicates the salt bridge formed between
TM3 and TM7 that stabilizes the inactive state [59].
Other residues are found on the intracellular side of
TM6, such as D6.30, which forms the ionic lock between
TM3 and TM6 e.g. in follicle-stimulating hormone re-
ceptor (FSHR), thyrotropin receptor (TSHR) and N6.30
in melanocortin 4 receptor (MC4R), whose mutations
cause destabilization of the inactive state [59]. However,
the majority of residues are located midway on helices
TM6 and TM7 at their common interface e.g. M/L6.40
(rhodopsin, TSHR, MC4R), T/V6.43 (Luteinizing hor-
mone receptor or LHR, TSHR, MC4R), C6.47 (LHR),
P6.50 (TSHR), N7.45, N7.49, and L7.52 (TSHR) [58,59].
Mutation of any of these residues results in increased
constitutive receptor activity by disrupting the packing
between TM6 and TM7 and possibly by interfering with
a water-mediated interhelical H-bonding network in in-
active receptor states e.g. TSHR and rhodopsin [61,62].
It can be further speculated that mutation(s) in this
“hotspot” area (see Figure 12) would likely affect activity
of other Class A GPCRs. Unfortunately, studying the
exact nature of the water-mediated effect between TM6
and TM7 in a statistical way is not possible as the crystal
structure resolution of the majority of receptors is not
high enough (2.2-3.5 Å). However the high-resolution
crystal structures of inactive A2AR(-BRIL fusion) andFigure 12 TM6-TM7 interface of Rhodopsin in its inactive state (PDB
id: 1GZM) with residue positions 6.40, 6.43, 6.47, 6.50, 7.45, 7.49, 7.52
highlighted (in yellow/gold) (Ballesteros-Weinstein numbering [60]).
Upon mutation these “hotspot” residues increase constitutive activity
of some Class A GPCRs by destabilising their inactive states.
Extracellular side of membrane is represented by red dots and the
intracellular side by blue dots.inactive delta opioid receptor [19] have recently been
determined (both at 1.8 Å resolution) [63] and show
three water molecules bound between N7.45, N7.49
and L6.43, and one water molecule next to P6.50 (see
Additional file 1: Figure S7I). It can be speculated that
these water molecules exist in other Class A GPCRs sta-
bilising their inactive states, and need to be rearranged
for receptor activation when the TM6-TM7 interhelical
angle changes or when residues in this interface are
mutated. Indeed, molecular dynamics studies of water
molecules in Class A GPCRs have recently shown that a
continuous central water channel opens up during
receptor activation, which is not present in the inactive
state [64-67]. This highlights the functional role of
dynamic waters in receptor activation although a high-
resolution crystal structure of a Class A GPCR in its
active state is ideally required to confirm this hypothesis.
In addition to the TM6-TM7 interface, mutations in
other interfaces alter the activity of some Class A
GPCRs. In particular, mutations are often found in the
TM3-TM6, TM5-TM6 and TM1-TM7 interfaces whose
respective interhelical angles are seen to follow trends in
receptor activation e.g. A6.34 in the interface with TM5
(LHR and TSHR) whose mutation causes a gain in recep-
tor activity and Y6.52 (GNRHR, gonadotropin-releasing
hormone receptor) whose mutation causes a loss of
activity. Similarly located on TM6 in the interface with
TM3 is D6.44 (LHR, TSHR) whose mutation causes a
gain in receptor activity [58,59]. Conversely, on TM5 in
the interface with TM6 is F5.48 (MC4R), whose muta-
tion results in a loss of receptor activity [59]. Finally,
located on TM7 and involved in the interface with TM1
is C7.47 (TSHR) whose mutation causes a gain in activ-
ity [58]. Taken together, these mutations point to the
functional importance of several interhelical conform-
ational changes, primarily involving interhelical angles
TM6-TM7 and TM3-TM6 but also TM5-TM6 and
TM1-TM7.
The analysis performed here also potentially offers a
new means of classifying GPCR structural states. For
instance, in active (and semi-active) receptors, the TM6-
TM7 angle resides between 15-30°, TM5-TM6 between
8-21° and TM3-TM6 between 24-35°, while the TM2-
TM3 and TM3-TM7 distances reside between 9.8-10.5
Å and 7.5-10.9 Å, respectively. On the other hand, in in-
active receptors the TM6-TM7 angle adopts 0-19°, TM5-
TM6 between 19-35° and TM3-TM6 between 31-46°,
while TM2-TM3 and TM3-TM7 distances reside be-
tween 10.4-12.7 Å and 10.8-12.9 Å, respectively. Al-
though these ranges overlap to some degree, as more
active GPCR crystal structures become available these
features can likely be refined further, as well as the stat-
istical analysis between receptor states made even more
robust. However, they currently offer a useful guide for
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tion of GPCR structures through quantifiable means
without the need for visual comparison of structural
superimpositions.
The recently developed strategy of crystallizing GPCRs
in active states with co-crystallized G-proteins/nanobo-
dies has made it possible for quantifying Class A GPCR
activation with statistical significances. This has been
aided by the recent crystallization of agonist-bound re-
ceptor structures that can be classified as “semi-active”.
These structures show conformational changes on the
extracellular side just like fully active structures but less
noticeably on the intracellular side. They are particularly
interesting as they give a suggestion of the intermediate
steps that occur during receptor activation prior to G-
protein binding. Clearly as more GPCRs are crystallized
in their active state, statistical analysis of GPCR activation
will become more powerful and potentially reveal more of
the mechanistic subtleties involved, as well as identifying
other common or differential aspects between receptors.
However, it seems apparent that in terms of overall
conformation change, Class A GPCRs share several fea-
tures, as well as similar agonist/antagonist binding
patterns, which can possibly be used as a starting point
for the design of new drugs with predictable action
against other Class A GPCRs.
Methods
A non-redundant Class A GPCR dataset (where each
receptor is only represented once in either active or
inactive state, or twice in both active and inactive states)
was constructed from all available PDB structures. The
dataset consists of 18 Class A GPCR structures in their
inactive state: rhodopsin (PDB id: 1GZM), adenosine
A2A receptor (PDB id: 3PWH), β2-adrenergic receptor
(PDB id: 2RH1), β1-adrenergic receptor (PDB id: 2VT4),
squid rhodopsin (PDB id: 2Z73), histamine H1 receptor
(PDB id: 3RZE), sphingosine1-phosphate receptor 1
(PDB id: 3V2Y), dopamine D3 receptor (PDB id: 3PBL),
CXCR4 chemokine receptor (PDB id: 3ODU), M2 mus-
carinic acetylcholine receptor (PDB id: 3UON), M3
muscarinic acetylcholine Receptor (PDB id: 4DAJ),
protease-activated receptor 1 (PDB id: 3VW7), kappa
opioid receptor (PDB id: 4DJH), mu-opioid receptor
(PDB id: 4DKL), nociceptin/orphanin FQ opioid recep-
tor (PDB id: 4EA3), delta opioid receptor (PDB id:
4N6H), CCR5 chemokine receptor (PDB id: 4MBS),
P2Y12 receptor (PDB id: 4NTJ); and 7 Class A GPCR
structures in their active state: β2-adrenergic receptor
(PDB id: 4LDE), metarhodopsin II (PDB id: 3PQR),
adenosine A2A receptor (PDB id: 3QAK), neurotensin
NTS1 receptor (PDB id: 4GRV), M2 muscarinic acetyl-
choline receptor (PDB id: 4MQT), serotonin 5-HT2B
receptor (PDB id: 4IB4), P2Y12 receptor (PDB id: 4PY0).β2-adrenergic receptor, metarhodopsin II and M2 mus-
carinic acetylcholine receptor contain a co-crystallised
intracellular binding partner (G-protein or fragment)
and are therefore fully active. The other four receptors in
the active category are considered “semi-active”. Criteria
for selecting specific receptor structures was based on
a multi-factorial assessment of: crystal structure resolution
(lowest preferable), structural completeness, presence of
co-crystallised agonist or antagonist, minimal unnatural
amino acids or artificial mutations, absence of fusion
constructs where possible e.g. lysozyme or BRIL, which
are typically fused between TM5 and TM6 to aid crys-
tallization. In rare instances where electron density is
missing for particular residues, side-chains were com-
pleted with CHIMERA [68] by identifying the most prob-
able rotamer from the Dunbrack backbone-dependent
rotamer library [69]. The average X-ray crystallogra-
phy resolution for active GPCR structures is 2.92 Å
(S.D. ± 0.27 Å) and for inactive structures 2.77 Å
(S.D. ± 0.40 Å). These values were considered acceptable
for statistical comparisons to be made between recep-
tor states.
The software Helix Packing Pair [51] was used to
calculate the “global” interhelical angle between com-
mon packed helix pairs i.e. helices that contain at least
one vdW interaction between helices. Helices were de-
fined by DSSP [70] and water and lipids were removed.
The interhelical angle is defined as the dihedral angle
between two planes, where each plane is defined by the
helix axis vector and the vector of closest approach, with
the latter calculated as perpendicular to both helix axes
(see Figure 1). Helix axis vectors are calculated by aver-
aging all “local” axis vectors, each of which is calculated
every four consecutive Cα atoms in a helix. Therefore
local helix distortions and bends are reflected in the
overall helix axis vector. The extent of interaction be-
tween helices is assessed by number of van der Waals
(within 106% of the sum of vdW radii), H-bonds and
ionic interactions (within 106% of distances: 2.70 Å for
O···H-O bonds, 2.88 Å for O···H-N, and 3.10 Å for
N···H-N). Interhelical distances were calculated be-
tween the Cα atoms of centrally-positioned (and highly
conserved) residues in each helix. These coordinates
constitute a plane through the middle of the 7TM
core consisting of residues: 1.46, 2.50, 3.40, 4.50, 5.50,
6.44, 7.46 (Ballesteros-Weinstein numbering [60]) (see
Additional file 1: Supporting Data). POVME 2.0 [52]
was used to calculate binding-pocket volumes both on
the extracellular and intracellular sides with default
parameters. The intracellular binding-pocket was de-
fined as the space between Intracellular Loop 2, C-
termini of TM3, TM5 and TM7, and N-termini of
TM2 and TM6. The extracellular binding-pocket was
defined as the space beneath Extracellular Loop 2 and
Dalton et al. BMC Bioinformatics  (2015) 16:124 Page 14 of 15between N-termini of TM3, TM5 and TM7, and C-
termini of TM2 and TM6. Protein-ligand H-bond analysis
was made with CHIMERA [68] using default parameters,
which utilise geometric criteria extracted from a crystal
survey [71] for H-bond detection and additional “relax
constraints” of 0.4 Å and 20° for tolerance.
Statistical analyses
The variation of interhelical angles between helix pairs
was assessed with mean values and standard errors, with
statistical significance between active and inactive states
measured with Student’s t-tests. The variation of the
number of interhelical interactions (vdWs, H-bonds,
ionic) was assessed with median values and interquartile
ranges, with statistical significance between active and
inactive states measured with Wilcoxon rank-sum tests
because the non-continuous nature of the variables in-
volved requires a nonparametric framework. For both
parametric and nonparametric tests the Bonferroni cor-
rection for multiple comparisons was applied. Statistical
significance was set at p < 0.05. Graphs were constructed
with SigmaPlot 11.2 (Systat Software Inc., San Jose, CA
U.S.A.) and statistical analyses were performed with SAS
statistical package (SAS/STAT® 9.2, SAS Institute Inc.,
Cary, NC, U.S.A.).
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